14 December release from the CLL Society.
FDA Approval of Monoclonal Antibodies for Pre-exposure Prevention of COVID-19
FDA authorizes new, long-acting monoclonal antibodies (AZD7442 or EVUSHELD) for pre-exposure prevention of COVID-19 in certain individuals. CLL Society worked hard to ensure that those “certain individuals” with access to this passive immunity were the most vulnerable patients, namely the immunocompromised.
This has the potential to change everything and give us the freedom already enjoyed by those who are vaccinated and have a normal immune system. Dr. Brian Koffman’s write-up and FDA news can be found here.
If these shots become available later this month, what a Christmas present that would be!
We All Deserve Better 